Iratumumab Biosimilar Monoclonal Antibody (CD30) for Research

Cat No.: GMP-Bios-ab-278

Pre-Made Iratumumab biosimilar, Whole mAb, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-278-1mg 1mg 618

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Iratumumab biosimilar, Whole mAb, Anti-TNFRSF8 Antibody: Anti-CD30/Ki-1/D1S166E therapeutic antibody
INN Name Iratumumab
TargetTNFRSF8
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2005
Year Recommended2006
CompaniesMedarex
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedHodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma
Development TechMedarex UltiMAb Mouse



About target - TNFRSF8

1. Protein Tumor necrosis factor receptor superfamily member 8

2. Gene TNFRSF8

3. Organism Homo sapiens (Human)

Function
Receptor for TNFSF8/CD30L (PubMed:8391931).
May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B (PubMed:8999898).

Miscellaneous
Most specific Hodgkin disease associated antigen.